A study of 25 patients at our institution with gastroparesis (19 with diabetic gastroparesis) showed that this benefit was sustained at 12 months. [14] Weight gain of up to 8 pounds at 6 months ...

Gastroparesis is a chronic disorder that affects a significant subset of the population. Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the ...

McCallum and colleagues studied whether mitemcinal, an orally administered motilin agonist, is effective at improving diabetes-related gastroparesis symptoms. The authors conclude that mitemcinal ...

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025Gimoti remains only approved drug shown to ...

The analysis focused on adults who were obese, with a body mass index higher than 30, but who did not have a diagnosis of ...

Experts say while gastroparesis isn’t very common, it can develop due to the use of specific medications prescribed for ...

Diabetes, lifestyles (alcohol consumption, tobacco), and surgical procedures contribute to gastroparesis. Diabetic cases, especially those with autonomic neuropathy, are a major focus. Companies ...

The real-world retrospective study evaluated the impact of GIMOTI (metoclopramide nasal spray) in patients with diabetic gastroparesis (DGP) who were concurrently using GLP-1 receptor agonists. GLP-1 ...

One of the key challenges in treating gastroparesis is ensuring effective drug absorption, as delayed stomach emptying often compromises the efficacy of orally administered medications. GIMOTI ...

NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from ...